Research on the role of microglia in Alzheimer's disease

From November 2025

Microglia-derived nanovesicles synchronize macroautophagy and CMA for AD therapy, highlighting their role in disease progression (ref: Li doi.org/10.1038/s41392-025-02453-y/).
Activated microglia induce astrocyte reactivity in AD, suggesting complex glial interactions (ref: Ferrari-Souza doi.org/10.1038/s41593-025-02103-0/).
Lecanemab activates microglial functions to reduce Aβ pathology, emphasizing the potential of immunotherapy (ref: Albertini doi.org/10.1038/s41593-025-02125-8/).
Neuroinflammation correlates with cognitive decline in AD, as shown by TSPO PET imaging (ref: Rikken doi.org/10.1186/s13195-025-01915-3/).
Nobiletin reduces neuroinflammation in microglial cells, indicating potential therapeutic benefits (ref: Kritika doi.org/10.1007/s12035-025-05421-3/).
Genetic variation in TMEM106B alters microglial responses, linking genetics to neuroinflammatory processes (ref: Hartman doi.org/10.1007/s00401-025-02955-7/).
Aerobic exercise mitigates microglial activation and improves cognitive outcomes in AD models (ref: Jiang doi.org/10.1016/j.brainresbull.2025.111633/).
The brain neurovascular epigenome is associated with dementia, suggesting vascular health influences AD risk (ref: Ziegler doi.org/10.1016/j.neuron.2025.10.001/).

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec